<?xml version="1.0" encoding="UTF-8"?>
<NDC>
<NDCCode>
42291-108-50
</NDCCode>
<PackageDescription>
500 TABLET in 1 BOTTLE (42291-108-50)
</PackageDescription>
<NDC11Code>
42291-0108-50
</NDC11Code>
<ProductNDC>
42291-108
</ProductNDC>
<ProductTypeName>
HUMAN PRESCRIPTION DRUG
</ProductTypeName>
<ProprietaryName>
Acyclovir
</ProprietaryName>
<ProprietaryNameSuffix/>
<NonProprietaryName>
Acyclovir
</NonProprietaryName>
<DosageFormName>
TABLET
</DosageFormName>
<RouteName>
ORAL
</RouteName>
<StartMarketingDate>
19990305
</StartMarketingDate>
<EndMarketingDate/>
<MarketingCategoryName>
ANDA
</MarketingCategoryName>
<ApplicationNumber>
ANDA075382
</ApplicationNumber>
<LabelerName>
AvKARE, Inc.
</LabelerName>
<SubstanceName>
ACYCLOVIR
</SubstanceName>
<StrengthNumber>
400
</StrengthNumber>
<StrengthUnit>
mg/1
</StrengthUnit>
<Pharm_Classes>
DNA Polymerase Inhibitors [MoA],Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC],Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC],Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient]
</Pharm_Classes>
<DEASchedule/>
<Status>
Deprecated
</Status>
<LastUpdate>
2018-03-07
</LastUpdate>
<PackageNdcExcludeFlag>
N
</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>
N
</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>
20181231
</ListingRecordCertifiedThrough>
<StartMarketingDatePackage/>
<EndMarketingDatePackage/>
<SamplePackage/>
</NDC>